Meeting
2014 ASCO Annual Meeting
U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881).
Authors
Paul M. Barr
James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY
Paul M. Barr , Hongli Li , Catherine M Spier , Daruka Mahadevan , Jonathan W. Friedberg , Michael Leo LeBlanc , Mansoor Ul Haq , Christopher Flowers , Nina D. Wagner-Johnston , Bruce D. Cheson , Steven M. Horwitz , Thomas P. Miller , Richard I. Fisher
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01466881
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8523)
DOI
10.1200/jco.2014.32.15_suppl.8523
Abstract #
8523
Poster Bd #
3
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas.
First Author: Neha Mehta-Shah
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
T-cell lymphoma secondary to checkpoint inhibitor (CPI) used for other malignancies.
First Author: Kartik Anand
Poster
2016 ASCO Annual Meeting
Phase 1/2 study of forodesine in patients with relapsed peripheral t-cell lymphoma (PTCL).
First Author: Kunihiro Tsukasaki
Poster
2016 Genitourinary Cancers Symposium
A phase 2 study of the Aurora A kinase (AAK) tyrosine kinase inhibitor (TKI) alisertib (MLN8237) in patients (pts) with pretreated urothelial cancer (UC).
First Author: Andrea Necchi